EnergyPathways (LON: EPP) says that it remains focused on delivering the MESH hybrid compressed air storage project in the North Sea. Progress is being made towards final investment decision while outstanding approvals are awaited. The Secretary of State considers the proposals to be nationally significant and therefore it is a development for which consent is required.
Future Metals NL (LON: FME) reported a reduction in loss from $3.94m to $2.44m. The net cash outflow from operating activities was $2m.
Oracle Power (LON: ORCP) partner on the Northern Zone gold project in Australia, Riversgold, has requested a trading halt on the ASX. This is prior to a fundraising and there are discussions between the two companies and another firm to make progress with the project.
Ascent Resources (LON: AST) says the arbitration tribunal for its Energy Charter Treaty claim against the Republic of Slovenia has no further questions and it has to announce its award decision by the end of the first quarter of 2026.
FALLERS
WH Ireland (LON: WHI) has agreed the conditional disposal of its wealth management business to Aquis-quoted Oberon Investments (LON: OBE) for £1m, plus the assumption of contract liabilities. The business is loss making and there have been talks with other potential buyers. Assets under management declined to £1m. The group lost £1.9m on revenues of £13.2m last year. That is before an impairment charge of £6.1m and £900,000 of restructuring costs. WH Ireland will not have an operating business and plans to leave AIM if approved by shareholders. Cash was £3.3m at the end of August 2025. The company will be wound down.
Cyber security business Smarttech247 (LON: S247) is proposing to shareholders that it should leave AIM because it believes that will bring more flexibility in strategy. Full year revenues were ahead of expectations at €14.2m, three-quarters of which was recurring. Margins were lower than expected and there will be a loss in the year to July 2025.
Pharmacogenetic testing company Genedrive (LON: GDR) has raised £3.2m at 0.2p/share and there could be an additional £100,000 forthcoming. A retail offer of up to £300,000 has been launched and closes on 26 September. Each share comes with one warrant exercisable at 0.4p each. The cash will fund commercialisation of the company’s tests and a FDA 510(k) submission for a test that identifies stroke and cardiovascular patients unlikely to respond to medication early next year.
Proteome Sciences (LON: PRM) reported a reduction in interim revenues from £2.22m to £1.86m due to lower reagent sales and royalties. Uncertainty in the US life sciences market has hit demand and this will continue into the second half.